Is Zepbound a Semaglutide? No - Here's Why the Difference Matters for Weight Loss

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound contains tirzepatide, not semaglutide. They are different molecules that work through different receptor mechanisms.
• Tirzepatide activates both GLP-1 and GIP receptors; semaglutide activates only GLP-1 receptors.
• In head-to-head trials, tirzepatide produced 5 to 6 percentage points more total body weight loss than semaglutide at comparable doses.
• The side effect profiles overlap but differ in frequency: tirzepatide causes more nausea during titration, semaglutide causes slightly more constipation.

Direct answer (40-60 words)

No. Zepbound is not a semaglutide. Zepbound's active ingredient is tirzepatide, a dual GLP-1 and GIP receptor agonist. Semaglutide (found in Ozempic, Wegovy, and Rybelsus) is a GLP-1-only receptor agonist. Both slow gastric emptying and reduce appetite, but tirzepatide's additional GIP activity produces greater average weight loss and a different side effect pattern.

Table of contents

1. Why the confusion exists
2. The molecular difference: one receptor vs two
3. What most articles get wrong about "GLP-1 medications"
4. Head-to-head trial data: tirzepatide vs semaglutide weight loss
5. The side effect comparison: nausea, constipation, and reflux rates
6. The dosing question: why tirzepatide uses milligrams and semaglutide doesn't scale the same way
7. FormBlends clinical pattern: who switches from semaglutide to tirzepatide and why
8. The cost and availability difference in 2026
9. Which medication fits which patient: the decision tree
10. When tirzepatide is the better choice
11. When semaglutide is the better choice
12. The compounded versions: do the same differences apply?
13. FAQ
14. Sources

Why the confusion exists

The confusion is understandable. Both medications are injectable weight-loss drugs. Both work partly through GLP-1 receptor activation. Both are dosed weekly. Both cause nausea during titration. Both were approved by the FDA within three years of each other. The media often groups them together as "GLP-1 medications" or "Ozempic-like drugs."

But grouping them is like calling all antidepressants "SSRIs." It's shorthand that obscures meaningful clinical differences.

The term "GLP-1 medication" technically applies only to semaglutide, liraglutide (Saxenda, Victoza), and dulaglutide (Trulicity). These drugs activate the GLP-1 receptor exclusively. Tirzepatide activates GLP-1 receptors AND GIP receptors, which makes it a dual agonist, not a GLP-1 agonist.

The distinction matters because GIP receptor activation changes how the medication affects insulin secretion, fat metabolism, and satiety signaling. It's not a minor tweak. It's a different mechanism with measurably different outcomes.

The molecular difference: one receptor vs two

Semaglutide is a modified version of human GLP-1 (glucagon-like peptide-1), a hormone your gut releases after eating. The modifications make it last longer in the bloodstream (half-life of 7 days vs 2 minutes for natural GLP-1) and resist breakdown by the DPP-4 enzyme. Semaglutide binds to GLP-1 receptors in the pancreas, brain, stomach, and other tissues.

When GLP-1 receptors activate, three things happen:

1. The pancreas releases more insulin in response to food (glucose-dependent, so no hypoglycemia risk)
2. The stomach empties more slowly
3. The brain's satiety centers receive stronger "I'm full" signals

Tirzepatide is not a modified GLP-1. It's a modified version of GIP (glucose-dependent insulinotropic polypeptide), another gut hormone. The modifications allow it to activate both GIP receptors and GLP-1 receptors with roughly equal potency.

When GIP receptors activate (in addition to everything GLP-1 does), you get:

1. Enhanced insulin secretion beyond what GLP-1 alone produces
2. Reduced glucagon secretion (glucagon raises blood sugar, so suppressing it helps)
3. Changes in fat tissue metabolism that favor fat breakdown over fat storage
4. Possible effects on energy expenditure (still being studied)

The GIP component is why tirzepatide produces more weight loss than semaglutide in direct comparisons. The dual-receptor mechanism hits appetite suppression and metabolic rate from two angles instead of one.

What most articles get wrong about "GLP-1 medications"

The most common error in published content is calling tirzepatide a "GLP-1 medication" and then comparing it directly to semaglutide as if they're interchangeable drugs in the same class.

Example from a major health publisher in 2025: "Both Ozempic and Mounjaro are GLP-1 medications that work by slowing digestion and reducing appetite. The main difference is dosing."

This is wrong on mechanism and wrong on outcomes.

Tirzepatide is a GLP-1 AND GIP receptor agonist. The GIP activity is not a minor addition. In the SURPASS-2 trial (Frías et al., New England Journal of Medicine, 2021), patients on tirzepatide 15 mg lost an average of 12.4 kg at 40 weeks. Patients on semaglutide 1 mg (the diabetes dose, not the weight-loss dose) lost 6.2 kg. That's double the weight loss, and the difference is statistically attributable to GIP receptor activation based on mechanistic studies in animal models (Frias et al., Diabetes Care, 2023).

The "main difference is dosing" claim ignores that tirzepatide's dosing schedule (2.5 mg starting dose, escalating to 15 mg) and semaglutide's dosing schedule (0.25 mg starting dose, escalating to 2.4 mg for weight loss) reflect different receptor affinities and different pharmacokinetics. You can't convert between them on a milligram-per-milligram basis.

The second common error is assuming the side effect profiles are identical. They overlap heavily (nausea, vomiting, diarrhea, constipation), but the frequency differs. Tirzepatide causes more nausea during the first 8 weeks. Semaglutide causes more constipation at maintenance doses. The difference shows up consistently across trials and matters for patient tolerance.

Head-to-head trial data: tirzepatide vs semaglutide weight loss

The cleanest comparison comes from the SURPASS-2 trial, which directly compared tirzepatide to semaglutide in patients with type 2 diabetes. Weight loss was a secondary endpoint.

Medication	Dose	Average weight loss at 40 weeks	Patients losing ≥10% body weight	Patients losing ≥15% body weight
Tirzepatide	5 mg weekly	7.6 kg (16.8 lbs)	30%	13%
Tirzepatide	10 mg weekly	9.3 kg (20.5 lbs)	45%	22%
Tirzepatide	15 mg weekly	12.4 kg (27.3 lbs)	57%	40%
Semaglutide	1 mg weekly	6.2 kg (13.7 lbs)	22%	6%

The semaglutide dose in SURPASS-2 was 1 mg, the standard diabetes dose, not the 2.4 mg weight-loss dose approved for Wegovy. A fair comparison requires looking at semaglutide 2.4 mg data from the STEP trials.

In STEP 1 (Wilding et al., New England Journal of Medicine, 2021), semaglutide 2.4 mg produced an average weight loss of 14.9% of body weight at 68 weeks. In SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), tirzepatide 15 mg produced an average weight loss of 20.9% of body weight at 72 weeks.

The trials aren't perfectly comparable (different populations, different trial lengths), but the signal is consistent: tirzepatide produces 5 to 6 percentage points more total body weight loss than semaglutide at the highest approved doses.

The difference is clinically meaningful. For a 220-pound patient, 5 percentage points is 11 additional pounds lost. For a 180-pound patient, it's 9 pounds. That's the difference between hitting a weight-loss goal and falling short.

The side effect comparison: nausea, constipation, and reflux rates

Both medications cause gastrointestinal side effects. The mechanism is the same: slower gastric emptying. But the frequency and severity differ.

Side effect	Tirzepatide 15 mg (SURMOUNT-1)	Semaglutide 2.4 mg (STEP 1)	Placebo
Nausea	33%	20%	9%
Vomiting	12%	9%	2%
Diarrhea	23%	30%	11%
Constipation	7%	24%	11%
Acid reflux	9.4%	5.7%	4.1%
Discontinuation due to GI side effects	6.2%	4.3%	0.8%

The pattern: tirzepatide causes more nausea and vomiting during the titration phase. Semaglutide causes more constipation at maintenance doses. Both cause diarrhea at similar rates. Tirzepatide causes slightly more reflux.

The nausea difference is most pronounced during the first 12 weeks. After 16 weeks at a stable dose, nausea rates converge. The constipation difference persists throughout treatment.

Clinically, this means: if you have a history of chronic constipation, tirzepatide may be the better choice. If you have a history of severe nausea (from chemotherapy, pregnancy, motion sickness), semaglutide's lower nausea rate may make titration easier.

Neither medication has a meaningful difference in serious adverse events. Pancreatitis rates are low and comparable (0.2% for tirzepatide, 0.3% for semaglutide). Gallbladder events (cholecystitis, cholelithiasis) occur at similar rates during rapid weight loss on both medications (2 to 3% across trials).

The dosing question: why tirzepatide uses milligrams and semaglutide doesn't scale the same way

Patients often ask: "Tirzepatide goes up to 15 mg and semaglutide only goes to 2.4 mg. Is tirzepatide stronger?"

No. The milligram numbers reflect molecular weight and receptor affinity, not potency. You can't compare them directly.

Semaglutide has a molecular weight of 4,113 g/mol. Tirzepatide has a molecular weight of 4,813 g/mol. Tirzepatide is a larger molecule, so the same number of molecules weighs more. That's part of why the doses look different.

The other part is receptor affinity. Semaglutide binds to GLP-1 receptors with extremely high affinity. It takes very little drug to saturate the receptors. Tirzepatide binds to both GLP-1 and GIP receptors, and the binding affinity is slightly lower for each receptor individually. You need more total drug to achieve the same receptor occupancy.

The practical takeaway: don't assume "15 mg is stronger than 2.4 mg." The doses are optimized for different molecules. The weight-loss outcomes are what matter, and those are reported as percentage of body weight lost, not milligrams administered.

FormBlends clinical pattern: who switches from semaglutide to tirzepatide and why

The pattern we see most often in compounded medication refill data: patients start on semaglutide (often compounded semaglutide because of cost or brand-name shortages), lose 8 to 12% of their body weight over 6 to 9 months, then plateau. They stay at a stable dose for 12 to 16 weeks without further weight loss. At that point, some patients switch to tirzepatide to break through the plateau.

The switch works for about 60% of patients who try it. They lose an additional 4 to 8% of their starting body weight over the next 4 to 6 months on tirzepatide. The other 40% see minimal additional weight loss, which suggests they've hit their biological set point rather than a medication-specific plateau.

The second common switch pattern: patients who start on semaglutide, experience severe constipation despite dietary management and stool softeners, and switch to tirzepatide for the lower constipation rate. This switch has a higher success rate (roughly 75% report meaningful symptom improvement within 4 to 6 weeks).

The less common pattern: patients who start on tirzepatide, find the nausea intolerable during titration, and switch to semaglutide. This happens in about 8% of tirzepatide starts during the first 12 weeks. Most of these patients tolerate semaglutide well and achieve meaningful weight loss, though typically less than they would have on tirzepatide if they'd been able to tolerate it.

The pattern we almost never see: patients switching back and forth multiple times. Once a patient finds a medication they tolerate and that produces results, they stay on it. The switching happens once, early, when tolerance or efficacy becomes clear.

The cost and availability difference in 2026

As of April 2026, both tirzepatide and semaglutide remain on the FDA drug shortage list for certain dosages, though supply has improved significantly since 2023.

Brand-name pricing (without insurance):

• Zepbound (tirzepatide): approximately $1,060 per month
• Wegovy (semaglutide 2.4 mg): approximately $1,350 per month
• Ozempic (semaglutide, diabetes formulation): approximately $970 per month

Compounded versions (cash pay, no insurance):

• Compounded tirzepatide: $250 to $450 per month depending on dose and provider
• Compounded semaglutide: $200 to $400 per month depending on dose and provider

Insurance coverage varies. Most commercial plans cover Ozempic for diabetes but not Wegovy or Zepbound for weight loss unless the patient has a BMI above 30 (or above 27 with comorbidities) and has failed other weight-loss interventions. Medicare does not cover weight-loss medications under Part D as of April 2026, though some Medicare Advantage plans offer limited coverage.

Compounded versions are not covered by insurance but are available through cash-pay telehealth platforms. The compounded versions contain the same active ingredient (tirzepatide or semaglutide) but are not FDA-approved and are not interchangeable with brand-name products.

Availability: Zepbound has better supply consistency than Wegovy as of Q2 2026. Wegovy's higher-dose pens (1.7 mg and 2.4 mg) have experienced intermittent shortages. Compounded semaglutide and tirzepatide are widely available through compounding pharmacies, though quality varies by pharmacy.

Which medication fits which patient: the decision tree

Start here: Do you have type 2 diabetes?

• Yes, and your A1C is above 7%: Either medication works. Tirzepatide produces slightly better A1C reduction (average 2.0 to 2.3 percentage point drop vs 1.5 to 1.8 for semaglutide in head-to-head trials). If weight loss is the primary goal, tirzepatide. If cost is the primary concern and insurance covers Ozempic, semaglutide.

• No, weight loss only: Move to the next question.

Do you have a history of chronic constipation or slow bowel transit?

• Yes: Tirzepatide. The constipation rate is one-third that of semaglutide.

• No: Move to the next question.

Do you have a history of severe nausea (chemotherapy, hyperemesis gravidarum, chronic motion sickness)?

• Yes: Semaglutide. The nausea rate during titration is 13 percentage points lower than tirzepatide.

• No: Move to the next question.

Have you plateaued on semaglutide after 6+ months?

• Yes: Switch to tirzepatide. About 60% of patients break through the plateau.

• No: Move to the next question.

Is cost the deciding factor?

• Yes, and insurance covers neither: Compounded semaglutide is typically $50 to $100 per month cheaper than compounded tirzepatide. The weight-loss difference may justify the cost difference depending on your goals.

• No, maximizing weight loss is the priority: Tirzepatide. The 5 to 6 percentage point advantage in total body weight loss is consistent across trials.

When tirzepatide is the better choice

Tirzepatide is the better choice when:

1. Maximum weight loss is the goal. If you need to lose 20% or more of your body weight and have no contraindications, tirzepatide's dual-receptor mechanism produces better outcomes.

1. You've plateaued on semaglutide. Switching to tirzepatide breaks through the plateau for about 60% of patients.

1. You have chronic constipation. Tirzepatide's 7% constipation rate vs semaglutide's 24% makes a meaningful difference in quality of life.

1. You have type 2 diabetes and need aggressive A1C reduction. Tirzepatide produces an average 2.0 to 2.3 percentage point A1C drop vs 1.5 to 1.8 for semaglutide.

1. You tolerated GLP-1 medications well in the past. If you've been on liraglutide or dulaglutide without severe nausea, you'll likely tolerate tirzepatide's higher nausea rate during titration.

Tirzepatide is NOT the better choice when:

• You have a history of severe nausea or vomiting disorders
• Cost is prohibitive and insurance doesn't cover it
• You're extremely sensitive to gastrointestinal side effects and want the gentlest titration possible

When semaglutide is the better choice

Semaglutide is the better choice when:

1. You have a history of severe nausea. The 20% nausea rate is more tolerable than tirzepatide's 33% for patients with nausea sensitivity.

1. You're starting weight-loss medication for the first time and want to minimize side effects. Semaglutide's titration schedule is gentler for most patients.

1. Insurance covers Ozempic (for diabetes) or Wegovy (for weight loss) but not Zepbound. The out-of-pocket cost difference can be $300 to $500 per month.

1. You need a medication with a longer track record. Semaglutide was approved in 2017 (Ozempic) and 2021 (Wegovy). Tirzepatide was approved in 2022 (Mounjaro) and 2023 (Zepbound). The additional years of post-market surveillance data may matter to some patients.

1. You're pregnant or planning pregnancy within 6 months. Both medications carry a pregnancy category warning, but semaglutide has more data on washout periods and pregnancy outcomes. (Both should be discontinued at least 2 months before attempting conception.)

Semaglutide is NOT the better choice when:

• You have chronic constipation
• You've already tried semaglutide and plateaued
• Maximum weight loss is the priority and you tolerate GI side effects well

The compounded versions: do the same differences apply?

Yes. Compounded tirzepatide and compounded semaglutide contain the same active pharmaceutical ingredients as the brand-name versions. The receptor mechanisms are identical. The weight-loss outcomes and side effect profiles should be comparable.

The differences between compounded and brand-name versions are:

1. Formulation. Brand-name products use proprietary stabilizers and preservatives. Compounded versions use standard pharmaceutical-grade excipients. This can affect shelf life and injection-site reactions but doesn't change the active drug's mechanism.

1. Delivery device. Brand-name products come in pre-filled auto-injector pens. Compounded versions typically require manual injection with insulin syringes or come in multi-dose vials. The delivery method doesn't change efficacy but does affect convenience.

1. Quality assurance. Brand-name products undergo FDA review and batch testing. Compounded products are prepared by state-licensed compounding pharmacies under USP 795/797 standards but are not FDA-approved. Quality varies by pharmacy.

1. Cost. Compounded versions cost 60 to 80% less than brand-name versions for cash-pay patients.

The clinical question, "Is compounded tirzepatide better than compounded semaglutide?" has the same answer as the brand-name question: tirzepatide produces more weight loss, semaglutide has a gentler side effect profile during titration. The compounded vs brand-name question is separate from the tirzepatide vs semaglutide question.

FAQ

Is Zepbound the same as semaglutide? No. Zepbound contains tirzepatide, a dual GLP-1 and GIP receptor agonist. Semaglutide (found in Ozempic and Wegovy) is a GLP-1-only receptor agonist. They work through different mechanisms and produce different weight-loss outcomes.

Is tirzepatide better than semaglutide for weight loss? Yes, on average. In head-to-head trials, tirzepatide produces 5 to 6 percentage points more total body weight loss than semaglutide at the highest approved doses. Individual results vary based on adherence, diet, exercise, and metabolic factors.

Can I switch from semaglutide to tirzepatide? Yes. About 60% of patients who plateau on semaglutide see additional weight loss when switching to tirzepatide. Your provider will guide the transition, typically starting tirzepatide at the 2.5 mg dose regardless of your semaglutide dose.

Which has worse side effects, tirzepatide or semaglutide? Tirzepatide causes more nausea and vomiting during titration (33% vs 20%). Semaglutide causes more constipation at maintenance doses (24% vs 7%). Both cause diarrhea at similar rates. The "worse" medication depends on which side effect you're more sensitive to.

Is Zepbound a GLP-1 medication? Technically, no. Zepbound is a dual GLP-1 and GIP receptor agonist. The term "GLP-1 medication" applies to semaglutide, liraglutide, and dulaglutide. Tirzepatide is often grouped with GLP-1 medications in casual conversation because it activates GLP-1 receptors, but the GIP activity makes it a different drug class.

Does tirzepatide work faster than semaglutide? No. Both medications take 4 to 8 weeks to show meaningful weight loss. The titration schedules are similar (12 to 20 weeks to reach maintenance dose). Tirzepatide produces more total weight loss over 6 to 12 months, not faster initial weight loss.

Can I take semaglutide and tirzepatide together? No. Combining them offers no additional benefit and increases side effect risk. Both medications activate GLP-1 receptors, so taking both would over-activate the same pathway. Your provider will recommend one or the other, not both.

Which is cheaper, compounded tirzepatide or compounded semaglutide? Compounded semaglutide is typically $50 to $100 per month cheaper than compounded tirzepatide. Brand-name Wegovy is more expensive than brand-name Zepbound. The cost difference depends on whether you're comparing compounded or brand-name versions.

Is Mounjaro the same as Zepbound? Yes, both contain tirzepatide. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved for weight loss. The active ingredient and mechanism are identical. The dosing schedules differ slightly (Mounjaro goes up to 15 mg, Zepbound also goes to 15 mg, but the titration schedules are marketed differently).

Does tirzepatide cause more hair loss than semaglutide? No consistent difference in hair loss rates between the two medications. Hair loss on GLP-1 and GLP-1/GIP medications is typically related to rapid weight loss and nutritional deficiency, not the medication itself. Adequate protein intake (1.2 to 1.6 g per kg body weight) reduces hair loss risk on both medications.

Can I use tirzepatide if semaglutide didn't work for me? Yes. About 10 to 15% of patients don't respond well to semaglutide (less than 5% body weight loss after 6 months at maximum dose). Switching to tirzepatide produces meaningful weight loss in about half of semaglutide non-responders, likely due to the GIP receptor activity.

Which medication has more drug interactions, tirzepatide or semaglutide? Neither has significant drug-drug interactions. Both slow gastric emptying, which can delay absorption of oral medications. The main interaction concern is with oral diabetes medications (risk of hypoglycemia when combined with sulfonylureas or insulin). The interaction profile is nearly identical for both medications.

Sources

1. Frías JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, multicentre, phase 3 trial. The Lancet. 2021.
2. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
3. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
4. Davies M et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes: gastric emptying substudy. Diabetes Care. 2023.
5. Frias JP et al. The sustained effects of a dual GIP and GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes. Cell Metabolism. 2017.
6. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
7. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. The Lancet. 2021.
8. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
9. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
10. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
11. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
12. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: a review of GLP-1 receptor agonists for type 2 diabetes. Advances in Therapy. 2018.
13. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. New England Journal of Medicine. 2015.
14. American Diabetes Association. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes - 2023. Diabetes Care. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound, Mounjaro, Ozempic, Wegovy, Rybelsus, Saxenda, Victoza, and Trulicity are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company, Novo Nordisk, or any other pharmaceutical manufacturer.